Professor Lencioni ILCA 2011.pdf - Biocompatibles

More documents

Recommendations

Info

Drug eluting bead doxorubicin (DEBDOX) vsconventional TACE: Pharmacokinetics• Serum doxorubicin levels at different time points after TACE with drugeluting bead doxorubicin (BTG- <strong>Biocompatibles</strong>) or conventional TACEVarela M et al. BCLC. J Hepatol 2007;100:698-711
Drug eluting bead doxorubicin (DEBDOX) vsconventional TACE: A RCT (PRECISION V)• International multicenter phase II study of DC Bead (BTG-<strong>Biocompatibles</strong>)with doxorubicin versus conventional Lipiodol TACE with doxorubicinPatientsrandomized1:1(n=212)TACE with DC BeadDoxorubicin dose = 150mgConventional TACEDoxorubicin dose = 50–75mg/m 2(maximum 150mg)TACE repeated at 2 and 4 monthsTACE repeated at 2 and 4 months• Primary endpoint: 6-month tumor response by central independent review• Secondary endpoints included safety (toxicity according to SWOG)Lammer J et al. Cardiovasc Intervent Radiol 2010;33:41-52
Page 1 and 2: Is DEBDOX the New Standardfor Chemo
Page 3 and 4: BCLC staging system and treatment s
Page 5 and 6: Probability of survival (%)Probabil
Page 7: Conventional TACE: treatment discon
Page 11 and 12: DEBDOX vs cTACE: Response rates are
Page 13 and 14: SongMalagariPoonVarelaLencioniReyes
Page 15: DEBDOX vs conventional Lipiodol TAC

Professor Lencioni ILCA 2011.pdf - Biocompatibles

Create successful ePaper yourself

Delete template?

Save as template?